Systems Biology and Genomics of Breast Cancer by Perou, Charles M. & Borresen-Dale, Anne Lise
Systems Biology and Genomics of
Breast Cancer
Charles M. Perou1 and Anne-Lise Børresen-Dale2
1Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599
2Department of Genetics, Institute for Cancer Research, Oslo University, The Norwegian Radium Hospital,
Montebello, 0310 Oslo, Norway
Correspondence: cperou@med.unc.edu
It is now accepted that breast cancer is not a single disease, but instead it is composed of a
spectrum of tumor subtypes with distinct cellular origins, somatic changes, and etiologies.
Gene expression profiling using DNA microarrays has contributed significantly to our
understanding of the molecular heterogeneity of breast tumor formation, progression, and
recurrence. For example, at least two clinical diagnostic assays exist (i.e., OncotypeDX
RS and Mammaprintw) that are able to predict outcome in patients using patterns of
gene expression and predetermined mathematical algorithms. In addition, a new molecular
taxonomy based upon the inherent, or “intrinsic,” biology of breast tumors has been devel-
oped; this taxonomy is called the “intrinsic subtypes of breast cancer,” which now identifies
five distinct tumor types and a normal breast-like group. Importantly, the intrinsic subtypes
of breast cancer predict patient relapse, overall survival, and response to endocrine and
chemotherapy regimens. Thus, most of the clinical behavior of a breast tumor is already
written in its subtype profile. Here, we describe the discovery and basic biology of the
intrinsic subtypes of breast cancer, and detail how this interacts with underlying genetic
alternations, response to therapy, and the metastatic process.
DISCOVERY OF BREAST CANCER
INTRINSIC SUBTYPES
In 2000, a team led by Drs. David Botstein,Patrick Brown, and Anne-Lise Børresen-Dale
used a semiunsupervised approach to identify
what should be the naturally occurring breast
cancer subtypes, using 40 patients with locally
advanced breast cancers (Perou et al. 2000).
They identified 496 genes, termed the “intrinsic
gene set,” by searching for genes that showed
little variance within repeated tumor samples
(i.e., before and after neoadjuvant chemother-
apy pairs), but high variance across different
tumors, and then used this gene set for tumor
subtype identification. Among these breast
tumors, they found that the patterns of expres-
sion of these genes identified four distinct
tumor subtypes and a normal breast-like group.
These so called “intrinsic subtypes,” named
because the gene list that defines them reflects
the intrinsic properties of these breast cancers,
Editors: Mina J. Bissell, Kornelia Polyak, and Jeffrey Rosen
Additional Perspectives on The Mammary Gland as an Experimental Model available at www.cshperspectives.org
Copyright # 2011 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a003293
Cite this article as Cold Spring Harb Perspect Biol 2011;3:a003293
1
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
have been consistently identified in independ-
ent data sets using different methods and multi-
ple microarray platforms (Sorlie et al. 2001,
2003; Sotiriou et al. 2003; Abd El-Rehim et al.
2004; Carey et al. 2006; Hu et al. 2006; Parker
et al. 2009). These subtypes are also conserved
across ethnic groups (Yu et al. 2004), and are
present even at the ductal carcinoma in situ
(DCIS) stage (Livasy et al. 2007; Allred et al.
2008). Importantly, the intrinsic subtypes
segregated tumors by expression of hormone
receptors (both estrogen receptor [ER] and pro-
gesterone receptor [PR]) and the genes they
regulate, supporting earlier epidemiologic and
biomarker studies, suggesting that ER-positive
and ER-negative breast cancers are distinct. At
least two hormone-receptor-positive subtypes
were identified that were called “luminal A”
and “luminal B.” Conversely, there were several
subtypes characterized by low expression of
hormone receptors and their regulated genes,
one of which was called the “HER2-enriched”
subtype and another called the “basal-like”
subtype (Fig. 1). The fifth subtype, the normal
breast-like group, is a less clear subtype; it is
acknowledged that the normal breast-like group
is a heterogeneous group including those with
a high stromal content, those with high lym-
phocyte infiltration, and those with true nor-
mal epithelial cell contamination of a low
malignant cell content tumor. In Figure 1, the
normal breast-like group is composed of many
true normal breast samples from reduction
mammoplasties and some tumors, which upon
hematoxylin and eosin (H&E) examination
show ,50% tumor tissue. In this figure, the
normal breast-like group is likely clustering
with the luminal A subtype due to their common
low proliferation rates and moderate expression
of luminal epithelial genes. Alternatively, a nor-
mal breast-like cell line may exist including the
PMC42 line, which has stem-cell-like properties
(Git et al. 2008). Ongoing studies have recently
identified a new and intriguing subtype called
the “claudin-low” group (Herschkowitz et al.
2007), but for the time being, these four tumor
subtypes and the normal breast-like group are
the ones consistently identified and commonly
accepted. Although the intrinsic subtypes were
identified regardless of outcome (i.e., no knowl-
edge of patient outcomes was used to select the
intrinsic gene set), these subtypes have strong
prognostic implications (Fig. 1F); in particular,
patients with basal-like, HER2-enriched, and
luminal B tumors show significantly poorer
outcomes when compared to patients with
luminal A tumors (Sorlie et al. 2001, 2003;
Sotiriou et al. 2003; Yu et al. 2004; Carey et al.
2006; Hu et al. 2006; Langerod et al. 2007;
Parker et al. 2009).
A critical aspect of biomarker biology is val-
idation, and the intrinsic subtypes have been
validated on many independent data sets (Sorlie
et al. 2003; Hu et al. 2006; Langerod et al. 2007;
Naume et al. 2007; Parker et al. 2009). For exam-
ple, Sorlie et al. (2003) showed that when using
this classification method on multiple data
sets, the subtypes were represented with similar
distributions, despite differences in the popula-
tions (i.e., the original gene expression study
was based upon high-risk and locally-advanced
tumors treated with chemotherapy, whereas
the NKI 295-patient data set included women
under 55 with lymph-node-negative tumors
that did not receive adjuvant systemic therapy
(van ’t Veer et al. 2002; van de Vijver et al.
2002), and the West et al. data set was a mixture
of stages, nodal status, and hormone receptor
status (West et al. 2001). Since the clustering
methodology for identifying intrinsic subtypes
is suboptimal for reproducible classifications,
a promising alternative approach for reproduci-
ble subtype classifications has been developed
based upon identifying the mean expression
profiles, called centroids, for each subtype (Hu
et al. 2006; Parker et al. 2009). Hu and col-
leagues (Hu et al. 2006) developed the Single
Sample Predictor (SSP) tool to serve as an un-
changing prognostic indicator for individual
patient samples; the SSP compares the gene ex-
pression profile of an unknown sample to a pro-
totypical profile of each intrinsic subtype
and classifies the unknown sample according
to the profile/centroid it most closely matches.
Recently this approach has been expanded upon
to include statistically robust and objective
methods for selecting prototypical samples/
tumors, and a robust method for gene selection,
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Figure 1. 677 breast tumors analyzed using hierarchical clustering and the Intrinsic/UNC 1300 gene list. A single
data set of 340 samples from UNC and 337 from the Netherlands Cancer Institute were combined using Distance
Weighted Discrimination (Benito et al. 2004), and then clustered together to yield a large and homogenous data
set containing over 470 different tumors with RFS and OS data. The clustering analysis identified the 5 major
intrinsic subtypes of luminal A, luminal B, normal-like, basal-like, and HER2-enriched, and also identified the
newest subtype in the center called the “claudin-low” group. The gene sets most definitive of each subtype are
shown and are (A) HER2-amplicon gene set, (B) basal epithelial gene set, (C) luminal epithelial gene set con-
taining ER, and (D) proliferation gene set. (E) Claudin-low gene set including E-cadherin and claudin 3, 4, and
7. (F) Kaplan-Meier plot for survival based upon disease-specific survival (DOD) for the six groups described
here. Scale bar showing the expression levels of each gene relative to the median expression.
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which has resulted in the PAM50 intrinsic sub-
type classifier. This algorithm uses 50 genes to
identify the four major intrinsic subtypes (lu-
minal A, luminal B, basal-like, HER2-enriched)
and the normal breast-like group, and has
the advantage that it can utilize RNA purified
from fresh frozen tumors or Formalin-Fixed
Paraffin Embedded (FFPE) materials, thus
making it compatible with materials coming
from a typical pathology archive (Parker et al.
2009).
TUMOR SUBTYPE BIOLOGY AND
CLINICAL FEATURES
Luminal Subtypes
The most common breast cancers are ER-posi-
tive tumors, which, according to gene expres-
sion patterns, fall into the luminal subtypes,
so-called because they have a gene expression
pattern reminiscent of the luminal epithelial
component of the breast (Perou et al. 2000).
These tumors are characterized by expression
of the ER, PR, and genes associated with ER
activation such as LIV1, TFF1/pS2, and Cyclin
D1 (Fig. 1C), as well as expression of luminal
cytokeratins 8 and 18 (Perou et al. 2000; Sotir-
iou et al. 2003; Oh et al. 2006). Luminal tumors
are often low-grade, and fewer than 20% have
TP53 mutations (Sorlie et al. 2001; Sotiriou
et al. 2003; Langerod et al. 2007; Naume et al.
2007). Within the broad and diverse luminal/
ERþ group, there are at least two subtypes,
luminal A and luminal B, and there are many
relevant differences between these two groups,
although it is not always easy to distinguish a
luminal A from a luminal B, since the expres-
sion of the genes defining these groups are
a continuum. For example, luminal A tumors
generally have high expression of ER and ER-
regulated genes, low expression of the HER2
cluster (which is variable in luminal B tumors),
and low expression of proliferation-associated
genes including Ki-67 (Sorlie et al. 2001, 2003;
Hu et al. 2006). Conversely, luminal B tumors
tend to be highly proliferative, tend to be
TP53 mutant, and in general show lower expres-
sion of ER and ER-regulated genes.
Luminal tumors in general are defined by a
quartet of transcription factors (Fig. 1C) that
includes ER, GATA3, FOXA1, and XBP1. Since
the initial description of this gene set, a great
deal has become known about the role of these
new players in breast luminal cell biology. For
example, when GATA3 is deleted early in mam-
mary development, ductal growth is greatly
inhibited and very few ERþ/luminal cells
develop (Kouros-Mehr et al. 2006); addition-
ally, if this deletion occurs during lactation
using a WAP-Cre promoter, lobular-alveolar
development is greatly impaired (Asselin-Labat
et al. 2006), suggesting that GATA3 is a critical
determinant of luminal cell formation. Carrol
et al. (2005) went on to perform genome-wide
chromatin immuno-precipitation (i.e., ChIP-
chip) experiments using ER and showed that
the majority of ER binding sites also had a close
binding site for FOXA1, and that FOXA1 was
required for the induction of most ER-regulated
genes including XBP1. Usary et al. (2004) also
showed that GATA3 is occasionally mutated in
ERþ/luminal tumors, and that these muta-
tions abolish DNA-binding activity. They also
showed, using ectopic expression of GATA3,
that FOXA1 is a GATA3-regulated gene. When
synthesized together, these data suggest that
GATA3 is a critical and early determinant of
the luminal lineage that may directly (or indi-
rectly) turn on ER and FOXA1, which in turn
act together to induce the expression of ER-
regulated genes including XBP1 (thus explain-
ing the mechanistic significance of this quartet
of transcription factors). Interestingly, ER may
also induce GATA3, and GATA3 also induces
ER; thus, once this developmental program is
turned on, it may be self sustaining (Eeckhoute
et al. 2007).
In population-based studies, the luminal A
subtype is the most common, representing
approximately 40% of all breast tumors, while
the luminal B subtype comprises approximate-
ly 10% (Table 1) (see Carey et al. 2006; Milli-
kan et al. 2007; Morris et al. 2007). Although
risk factors for all of the subtypes remain an
area of intense research, it is clear that all tradi-
tional risk and/or protective factors (like pro-
tection of risk from pregnancy) are factors for
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luminal breast cancers. Importantly, many of
the studies focused on the intrinsic subtypes
in population-based studies also show that pre-
menopausal women and African-American
women tend to develop fewer of the good-
prognosis luminal A tumors and more of the
poor-prognosis basal-like tumors (described
further below), which may contribute to the
poorer outcomes associated with this ethnic
group (Carey et al. 2006; Millikan et al. 2007;
Yang et al. 2007).
While a clinical assay to identify luminal A
and luminal B by gene expression is not yet
available, the OncotypeDX Recurrence ScoreTM
(RS) assay includes many genes (HER2, GRB7,
ER, SCUBE2, Bcl2, Ki-67, Survivin, MYBL2,
Cyclin B1) that are also used to define luminal
A versus luminal B tumors. To more directly
compare the OncotypeDX Recurrence Score
and the intrinsic subtypes of luminal A and
luminal B, Fan and colleagues compared both
classifiers on the NKI295 data set and showed
that 50% of the luminal A tumors had low RS
(i.e., good outcome), whereas only 2% of lumi-
nal B tumors had low RS (Fan et al. 2006).
Moreover, other prognostic genomic predictors
were also tested including a signature of acti-
vated fibroblasts (Chang et al. 2004) and the
NKI-developed Mammaprint signature (van ’t
Veer et al. 2002). Nonetheless, all of these pre-
dictors showed a high degree of concordance
when compared to each other, and in prog-
nostication. These findings have a number of
important implications, one of which is that
despite having almost completely no overlap-
ping genes, these four gene expression profiles
showed a high degree of agreement when the
actual patient clasifications were compared.
Second are the therapeutic implications where
a high OncotypeDX RS is associated with a
higher risk of relapse despite tamoxifen (Paik
et al. 2004), and a higher benefit of adjuvant
chemotherapy (Paik et al. 2006), suggesting that
similar predictions likely also hold true for the
distinction of luminal A versus luminal B.
HER2-enriched Subtype
The hormone-receptor-negative tumors are
largely comprised of the HER2-enriched, basal-
like, and claudin-low subtypes. The HER2-
enriched subtype is relatively infrequent, com-
prising only 10% of all breast cancers (Carey
et al. 2006). Typically, this subtype shows ele-
vated expression of HER2 and many other genes
that reside near HER2 in the genome, including
GRB7 (Fig. 1A), because of the known HER2
genomic loci DNA amplification (Slamon et al.
1987, 1989). We do note, however, that not all
tumors of this subtype show HER2 amplifica-
tion and/or overexpression, and thus, the term
HER2-enriched is used to describe this group to
Table 1. Frequency of the intrinsic subtypes according to race and age. (Table is from Millikan et al. [2007] and
reprinted with permission from Springer # 2007.) Distribution of breast cancer subtypes according to race and

















108 (41.4%) 179 (56.3%) 216 (57.4%) 293 (66.5%)
Basal-like
N ¼ 225
70 (27.2%) 52(16.0%) 54 (14.5 %) 49 (9.3%)
HER2þ/ERN ¼ 116 22 (8.4%) 26 (7.7%) 24 (5.6%) 44 (6.0%)
Luminal B
N ¼ 137
19 (7.3%) 26 (8.7%) 46 (12.4%) 46 (10.7%)
Unclassified
N ¼ 150
41 (15.7%) 38 (11.3%) 38 (10.1%) 33 (7.5%)
Total: 1424
P , 0.0001
260 (100%) 321 (100%) 378 (100%) 465 (100%)
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signify this imperfect but high correlation with
HER2 amplification status. Other expression
features of this subtype include low expression
of the luminal, hormone receptor-regulated
gene cluster and low expression of basal-like
genes. It is also critical to note that some, but
not all, clinically defined HER2-positive breast
cancers fall into this category; the clinically
defined HER2-positive breast cancers that
have high expression of the luminal cluster
and are ER-positive fall into the luminal sub-
types (typically luminal B); thus, there exists
at least two types of HER2-amplified tumors.
Another important feature of tumors in
the HER2-enriched subtype is high expression
of the proliferation cluster (Fig. 1D). Befitting
this expression pattern, 75% are high-grade tu-
mors, and over 40% have p53 mutations (Carey
et al. 2006). In the era before HER2-targeted
therapies, the HER2-enriched subtype carried
a poor prognosis (Sorlie et al. 2001, 2003; Hu
et al. 2006; Parker et al. 2009). However, given
the large benefit of anti-HER2-targeted thera-
pies in HER2-positive patients (Mass 2004;
Piccart-Gebhart et al. 2005), it is reasonable to
presume that the HER2-enriched subtype has
benefited from the HER2-targeting revolution,
but formal identification of this relationship is
yet to be demonstrated. There are no known
specific risk factors for the HER2-enriched
subtype, and there is no apparent interaction
with race or age (Carey et al. 2006; Millikan
et al. 2007). However, the risk factor profile of
this subtype most closely mirrors the luminal
tumors. These data suggest that although the
majority of ER-negative tumors are either of
the HER2-enriched or basal-like subtype, the
risk factors of HER2-enriched versus basal-like
are distinct, again suggesting that these are
two different diseases, in terms of etiology,
that should merit individual attention for pre-
vention and treatment strategies.
Basal-like Subtype
Perhaps the greatest impact of the intrinsic sub-
typegenomic taxonomywasthe identification of
thebasal-likesubtype. Before theuse ofDNA mi-
croarrays, ER-positive and HER2-positive tumors
were clearly appreciated as distinct disease types,
but what was not appreciated was that of the
remaining tumors. A significant disease entity
existed that showed an obvious and strong com-
mon biology. In clinical terms, this group has
become known as “triple-negative” tumors
(Schneider et al. 2008), due to their typical
immunohistochemical (IHC) pattern of being
negative for ER, PR, and HER2 (which are the
three commonly scored for predictive markers
in the breast cancer clinic), although this is not
a definitive classification since 25% of basal-
like tumors are not triple-negative. The basal-
like subtype is characterized by low expression
of the luminal genes, low expression of the
HER2 gene cluster, high expression of the pro-
liferation cluster, and high expression of a
unique cluster of genes called the basal cluster
(Fig. 1B). The basal gene cluster includes basal
epithelial cytokeratins (CK) such as CK5, 6, 14,
and 17; epidermal growth factor receptor
(EGFR); c-Kit; Vimentin; P-Cadherin; Fascin;
Caveolins 1 and 2; and aB-crystallin. Note that
it was the expression of cytokeratins 5, 6, 14,
and 17 that gave rise to the term “basal-like,” as
these are typically cytokeratins that are expressed
within basal epithelial cells of the skin and
airways.
Several risk factors for developing basal-like
tumors have been identified, with the most
interesting being the link between the basal-like
subtype and BRCA1 mutation carriers (Olo-
pade and Grushko 2001; Foulkes et al. 2003,
2004; Sorlie et al. 2003). Specifically, this associ-
ation is that in women who carry a deleterious
mutation in BRCA1 and who develop breast
cancer, over 80% of the time their cancer is of
the basal-like subtype. However, while BRCA1
mutation carriers usually develop basal-like
breast cancer, most basal-like breast cancers
are sporadic, and the BRCA1 gene and protein
appear intact in these tumors (Richardson
et al. 2006). A commonly held, but not yet for-
mally proven, hypothesis is that the broader
BRCA1 pathway is aberrant in sporadic basal-
like breast cancer, which, if true, has impor-
tant therapeutic implications. For example, the
BRCA1 (and BRCA2) are critical for properho-
mologous recombination-mediated DNA repair,
C.M. Perou and A.-L. Børresen-Dale
6 Cite this article as Cold Spring Harb Perspect Biol 2011;3:a003293
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
which is a high-fidelity mechanism. When the
homologous recombination pathway is lost or
dysfunctional, DNA repair occurs by the more
error-prone method that involves poly(ADP-
ribose) polymerase (PARP), which can be in-
hibited by a novel class of drugs that are being
tested in clinical trials. Exciting results have
now shown that PARP inhibitors elicit measura-
ble responses in known BRCA1 and 2 mutant
breast tumors (Fong et al. 2009), and more im-
portantly, also provided improvements in re-
sponse rates and overall survival in metastatic
triple-negative patients (O’Shaughnessy et al.
2009). This latter finding does suggest that spora-
dic basal-like patients have an impaired BRCA1/
2-pathway, but the precise genetic lesion is not yet
known. Other known molecular genetic defects
present in basal-like tumors include a high
TP53 mutation rate (.50% as determined by
sequence analysis) (Sorlie et al. 2001; Carey
et al. 2006), and loss of RB1 function (Gauthier
et al. 2007; Herschkowitz et al. 2008) that likely
results in the high proliferation rates that are
manifested by the high expression of the so-called
“proliferation signature” (Fig. 1D), which mostly
contain E2F-regulated genes (Whitfield et al.
2006).
Loss of normal DNA repair is also impli-
cated in sensitivity to chemotherapy, parti-
cularly to DNA-damaging agents such as
platinum drugs (Kennedy et al. 2004), although
recent studies suggest that basal-like breast
cancers may have a general sensitivity to chemo-
therapy (Rouzier et al. 2005; Carey et al. 2007).
Another notable association is between the
basal-like subtype, race, and age (Table 1). Sev-
eral independent population-based studies have
suggested that the basal-like subtype is overre-
presented in young women with breast cancer,
in African-American women, and especially
in young African-American women (Carey
et al. 2006; Bauer et al. 2007; Millikan et al.
2007; Lund et al. 2008). In the Carolina Breast
Cancer Study, basal-like breast cancer was the
most common among premenopausal African-
American women (27%), and least common
among postmenopausal non African-American
women (9%) (Millikan et al. 2007). Interesting-
ly, this overrepresentation of basal-like cancers
is even more prevalent in Africans (Nigerians)
(Huo et al. 2009). These findings suggest that
there may be genetic predisposition to basal-
like tumors, which is supported by alleles of
MYBL2, showing increased frequency in basal-
like cases versus controls (Thorner et al. 2009).
Millikan et al. have also shown that there are life
history risk factors for developing basal-like
cancers, including multiple pregnancies (which
is a protective factor for luminal disease), no
lactation, and having a high waist/hip ratio
(which is a measure of obesity that was predis-
posing for all breast cancer subtypes) (Millikan
et al. 2007).
Claudin-low Subtype
Recently, comparative mouse and human ge-
nomic analysis identified a unique subtype in
both humans and mice, with the mouse tu-
mors noted to display a “spindloid” morphol-
ogy (Herschkowitz et al. 2007). The conserved
claudin-low tumor subtype is characterized by
the low expression of genes involved in tight
junctions and cell–cell adhesion including
claudin 3, 4, 7, Occludin, and E-cadherin
(Fig. 1E), as well as by the high expression of
many mesenchymal genes including Vimentin,
Snail1, Snail 2, and Twist1. This lack of epithe-
lial cell features and expression of mesenchymal
traits is reminiscent of features associated with
stem cells, which is precisely what was shown
by Lim et al. (2009); specifically, Lim et al. puri-
fied and expression-profiled normal human
mammarystem cells (CD49fþ/EpCAM2) using
fluorescence-activated cell sorting (FACS). In-
terestingly, the authors compared these pro-
files to the average profile of each intrinsic
subtype and determined that it was the clau-
din-low subtype that was the most similar to
the Mammary Stem Cell profile. In this study,
Lim et al. also identified a luminal progenitor
fraction (CD49fþ/EpCAMþ) that was not able
to form ducts in vivo but that could give rise
to luminal colonies in vitro, and it was this frac-
tion that was the most similar to basal-like
tumors. Additionally, in tissues from BRCA1
mutation carriers, there were an increased num-
ber of these luminal progenitor/basal-like cells,
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thus suggesting that BRCA1 loss causes an arrest
at this stage of development.
Other studies on Tumor Initiating Cells
(TIC) isolated from multiple human breast tu-
mors has shown that the claudin-low tumors
are also enriched for TIC features including
high ALDH1, a high mRNA ratio of CD44þ/
CD242, and a high mRNA ratio of CD29þ/
CD242 (Creighton et al. 2009). In addition, it
was also shown that metaplastic carcinomas (a
rare and aggressive breast tumor subtype) show
claudin-low features, with both claudin-low
tumors and metaplastic carcinomas exhibiting
characteristics of epithelial-to-mesenchymal
transition (Hennessy et al. 2009). In total, these
results suggest that the intrinsic subtypes of
breast cancer may reflect arrest of epithelial cells
at different stages of mammary epithelial devel-
opment, with claudin-low tumors representing
arrest at the most primitive stem cell state, then
followed by basal-like tumors that are arrested at
the luminal progenitor state, followed by lumi-
nal A/B tumors that show the greatest amount
of differentiation (Lim et al. 2009; Prat and
Perou 2009).
IMPORTANCE OF TUMOR STROMA IN
BREAST CANCER
The subtypes discussed above have been iden-
tified through gene expression profiling of pri-
mary tumors that contain multiple cell types
including epithelial cells, fibroblasts, adipo-
cytes, and immune cells, among others. The
topic of regulation of tumor growth and pro-
gression via the stroma is covered in other
articles on this topic; however, we do note
here that it is important to highlight that nu-
merous publications have now identified that
tumor stromal cells (i.e., cells other than the
malignant epithelial cells present within tu-
mors) can contribute to cancer development
and progression (reviewed in Joyce and Pollard
2009), and stromal cell profiles alone can pre-
dict clinical outcome in breast cancer (Finak
et al. 2008). Importantly, it is also becoming
more and more evident that immune cells are
key modulators of tumor progression and me-
tastasis (DeNardo et al. 2009).
GENOMIC ALTERATIONS ASSOCIATED
WITH INTRINSIC SUBTYPES
Genomic instability was shown decades ago to
be a hallmark of cancer (Nowell and Hunger-
ford 1960). Since then, there have been numer-
ous studies using different methods to identify
breast cancer subclasses based on the genomic
structure ranging from karyotype studies and
Array-based Comparative Genomic Hybridiza-
tion (aCGH) analyses, to large-scale SNP arrays.
For example, karyotyping has shown that inva-
sive lobular carcinomas (ILC) have a chromo-
some 16q loss in more than 60% of cases,
correlating with loss of E-cadherin expression,
a protein important for cell adhesion and motil-
ity (Vos et al. 1997). This loss is often combined
with 1q gain, and a translocation resulting
in a der(1,16) is considered as an early event
in mammary carcinogenesis (Tsarouha et al.
1999). In a study by Nordgard et al. (2008), del-
etion of 16q was overrepresented in the good
prognosis luminal A subgroup, but at the same
time was a predictor of good prognosis also for
the nonluminal subgroups.
Both conventional and array-based CGH
have been applied on invasive breast carcinoma
cohorts. Several groups have found genomic
alterations by aCGH that seem to be more fre-
quent in one or more of the intrinsic classes
(Bergamaschi et al. 2006; Chin et al. 2006; Fri-
dlyand et al. 2006). Bergamaschi et al. (2006)
showed in an advance stage cohort, that the
intrinsic subclasses harbored different genomic
alterations. The basal-like tumors had higher
numbers of gains and losses than luminal A
and the luminal B, and HER2-enriched had
more frequent high-level amplifications. Chin
and Fridlyand compared their aCGH groups
to the expression subtypes and found that lu-
minal A tumors were dominating the 1q/16q
group; luminal A and HER2 enriched the
“mixed amplifier” group; and basal-like and
luminal B tumors comprised the majority of
the “complex” group. Another study (Chin
et al. 2007) identified a group of tumors with
low genomic instability, and found these tu-
mors to be enriched for the basal-like subtype.
Normal breast-like samples are often too few
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to be studied, and luminal B can be difficult to
identify in some data sets (Langerod et al. 2007);
thus, their copy number profiles are much less
defined.
Four different patterns of alterations were
identified by Hicks et al. (2006). The “Simplex”
group had broad segments of duplications and
deletions and often associated to luminal A
tumors; deletion of 16q, 8p, and 22 as well as
gain of 1q, 8q, and 16p was dominating. The
“Complex I” had either a “saw tooth” appear-
ance with narrow segments of deletions and
duplications affecting more or less all chromo-
somes, with the basal-like tumors dominating
this group of tumors. “Complex II” tumors
resembled the “simplex,” but had at least
one localized region of clustered peaks of ampli-
fications called “firestorms,” and were typical
for the HER2-enriched group. The fourth
pattern was called “flat,” defining profiles
with no clear gains or losses in terms of copy
number.
Several studies have had quite divergent
definitions on which genomic alterations char-
acterize distinct subgroups of breast carcino-
mas, but a common finding is that the 1q and
16q alterations dominate in one type, and mul-
tiple alterations on several arms dominate
others (Tirkkonen et al. 1998; Teixeira et al.
2002; Rennstam et al. 2003; Korsching et al.
2004; Baudis 2007; Climent et al. 2007; Andre
et al. 2009). In a recent study of genomic copy
number aberrations (Russnes et al. 2010), two
platform-independent algorithms were devel-
oped to explore genomic architectural distor-
tion using aCGH data to measure whole arm
gains and losses (WAAI) and complex rear-
rangements (CAAI). By applying CAAI and
WAAI to data from 595 breast cancer patients,
the tumors could be separated into eight sub-
groups with different distributions of genomic
distortion. Within each subgroup data, from
expression analyses, sequencing, and ploidy
indicated that progression occurs along sep-
arate paths into more complex genotypes. In
particular, basal-like tumors were separated
into genomic classes with distinct patterns of
alterations, emphasizing genomic heterogene-
ity within this intrinsic subtype.
Genomic Profiles of Clinical Utility
Microarray-based analyses have resulted in an
explosion of prognostic and predictive profiles,
and for breast cancer alone, there are .100
publications purporting to have prognostic pro-
files. We apologize to the many authors who
developed important signatures that were not
discussed here; however, a small number of pro-
files/signatures have come into relatively com-
mon clinical use and thus, are discussed here.
Of particular note are the OncotypeDX (Paik
et al. 2004, 2006) and Mammaprint gene ex-
pression tests (van ’t Veer et al. 2002; van de
Vijver et al. 2002). These tests were both devel-
oped as outcome predictors for breast can-
cer patients, which are basically predictors of
the likelihood to develop metastasis (which is
discussed in greater detail below). Specifically
for the OncotypeDX assay, this 16-gene assay
was developed to predict the likelihood of re-
currence for ERþ/node-negative patients re-
ceiving tamoxifen (Paik et al. 2004). Building
upon these results, Paik et al. (2004) also showed
that this assay can be used to identify a subset of
ERþ patients that gain a benefit from chemo-
therapy (CMF therapy specifically), which was
a relatively small subset of patients (25% of
the total tested). The great utility of such an
assay is that typically all of these patients might
be treated with chemotherapy; thus, by using
this assay, only 25% of patients will receive che-
motherapy, as they are the subset that benefit,
thus sparing the remaining 75% the toxicity
and cost associated with chemotherapy regi-
mens. This assay is now being tested in a pro-
spective trial called TAILORx (www.cancer.
gov/clinicaltrials/digestpage/TAILORx).
Mammaprint was developed as a pure prog-
nosis predictor, using time to distant metasta-
sis formation as the supervising parameter in
patients receiving no systemic adjuvant therapy
(van ’t Veer et al. 2002; van de Vijver et al. 2002).
The utility of this assay is to identify those
patients in whom the risk of relapse/metastasis
formation is so low that they can be spared adju-
vant chemotherapy because they would do very
well if they received no therapy at all. This pre-
dictor is also being tested in a prospective
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clinical trial in Europe called MINDACT (www.
eortc.be/services/unit/mindact/MINDACT_
websiteii.asp). Interestingly, there was only one
gene that overlapped between the OncotypeDX
assay and the Mammaprint assay, and so this
prompted us to perform a simple analysis where
we took a single data set and applied four of the
most well-known prognostic profiles, and we
asked what level of patient classification con-
cordance existed (Fan et al. 2006). These predic-
tors included the aforementioned OncotypeDx
assay, the Mammaprint assay, the intrinsic
subtype classification, and a fibroblast-derived
wound response signature from Howard Chang
and colleagues (Chang et al. 2004). The result
was that there was a large amount of agreement
between these assays, with, for example, the
OncotypeDx and Mammaprint assays agree-
ing in outcome predictions for 80% of the
patients. These findings strongly suggest that
individual gene identity is not a good means
of determining similarity across profiles, and
suggests that these apparently different gene
sets may be recognizing a common biological
background.
The Genomics of Metastasis
Metastases are the main cause of mortality for
patients with breast cancer, and diagnosis of dis-
seminated disease correlates with less than a 3%
survival rate over 20 years (Greenberg et al.
1996). Genomic profiling of human tumors
and model systems has provided important
mechanistic information for metastasis bio-
logy. First, there are gene signatures in primary
tumors that can be highly predictive of the
development of future metastases (van ’t Veer
et al. 2002; van de Vijver et al. 2002; Ramasw-
amy et al. 2003; Paik et al. 2004; Wang et al.
2005). Second, primary tumors and metastases
appear genomically very similar to one another,
despite being separated in time or space (Fig. 2)
(Perou et al. 2000; Weigelt et al. 2005; Hu et al.
2009). Third, human cell lines can be selected
that have specific end-organ tropisms with dis-
tinct expression profiles in brain, bone, and
lung, and specific sets of genes mediate these
aggressive behaviors (Kang et al. 2003; Minn
et al. 2005; Bos et al. 2009). Above, we discuss
many of the “metastasis predictors,” which are
basically the different outcome predictors for
breast cancer patients, and below we discuss
genomic predictors that have provided biologi-
cal insights into metastasis biology.
Only a few years ago the predominant mod-
el of cancer progression stated that the capacity
of a primary tumor to metastasize is acquired
only rarely and late in tumorigenesis (Fidler
and Kripke 1977). Belief in this model requires
metastatic cells to be molecularly distinct from
the majority of the tumor population they arose
from. Global gene expression profiling is an
ideal method to use to determine how different
primary tumors are from their metastases.
However, due mostly to the difficulties of har-
vesting metastatic tissues, there are only a few
published studies that report on the gene
expression similarity between primary tumors
and their matched metastases. One study per-
formed microarray analyses on eight pairs of
tumors that were patient-matched primary
and distant metastases (Weigelt et al. 2003),
with the interval between the surgical removal
of the primary tumors and metastases varying
from 1.6 to 15 years. Unsupervised hierarchical
clustering of these found that 6 of the 8 metasta-
ses were more similar to their primary tumor
than to any other sample. On average, 92% of
significantly expressed genes were similarly ex-
pressed between primary tumors and their me-
tastases, and overall, no one gene was differently
expressed in all metastases.
A second study with additional unmatched
and matched primary tumor-metastasis sam-
ples confirmed these original results, finding
that all primary breast tumors paired with their
matching metastasis and maintained their in-
trinsic subtype (Weigelt et al. 2005). It is impor-
tant to note that metastases occur in all subtypes
(Fig. 2), although the rate and location of cancer
progression are influenced by subtype (Smid
et al. 2008). Interestingly, some of the markers
for tumor aggressiveness were increased in
six of the seven pairs of metastases, yielding
a “poorer” 70-gene prognosis signature in the
metastatic cells. These studies provide initial
insights and suggest that metastases are much
C.M. Perou and A.-L. Børresen-Dale
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Figure 2. Hierarchical clustering analysis of primary tumors and metastases taken from Weigelt et al. (2005) and
reproduced with permission from AACR Publications # 2005. A hierarchical clustering analysis was performed
using a 1300-gene intrinsic gene list from Hu et al. (2006). Genes were arranged in horizontal and samples in
vertical. Sample names in red represent six primary tumor-distant metastasis pairs; those in light blue represent
primary tumor-lymph node metastasis pairs; and those in pink represent local and distant metastasis samples
from autopsy patients (which for patient A1 includes the primary).
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more similar to their primaries than was orig-
inally envisioned. It is this great similarity
between primaries and their matched meta-
stases, or between two pieces of any given
tumor, that gave rise to the term “molecular
portraits” because we learned that the genomic
pattern of any individual tumor is as unique as
a portrait of a given individual (Chung et al.
2002).
Site-specific Metastatic Signatures
A great deal of work has been done to deter-
mine if signatures of metastasis, particular sig-
natures of metastasis to specific sites, exist. In
2003, Kang et al. described a genomic signature
mediating breast cancer metastasis to bone
(Kang et al. 2003). This study used an aggressive
and metastatic human breast cancer cell line,
MDA-MB-231, that can form osteolytic bone
metastases 30% of the time after inoculation
into the arterial circulation of mice. After recov-
ering these bone metastases, and re-injecting
them into mice serially, they developed cell lines
with an increased propensity to grow in the
bone. To determine the genes that contributed
to increased bone metastases, microarray analy-
ses were performed on the bone-tropic cells and
the parental cells. Overall, they found few differ-
ences in the global gene expression profile, but
they did find a small set of the genes that
were more highly expressed in the bone tropic
line that included cell membrane and secretory
products that may function to affect the host
environment to favor metastasis. Through
in vitro single-cell cloning and microarray
analyses, they found that the increase in aggres-
siveness observed in the in vivo isolated bone-
seeking cells was due to specific cells within
the parental cell line expressing five key meta-
stasis genes. They concluded that overex-
pression of the small bone metastasis gene set
was superimposed on a poor-prognosis gene
expression signature already present in the
parental breast cancer population, suggesting
that metastasis requires a small set of functions
beyond those already present within this aggres-
sive cell line.
Further studies from the Massague labora-
tory used the same approach to identify genes
that mediate breast cancer metastasis to the
lung (Minn et al. 2005) and brain (Bos et al.
2009). Both studies identified relatively small
gene sets that regulate lung and brain meta-
stases with validation of their signatures using
clinical outcomes. Interestingly, six of the 17
genes in the brain signature were also found in
the lung signature, and this overlap suggests a
partial sharing of mediators of metastasis to
the brain and lungs, which is corroborated by
observations from clinical practice. It should
be stressed that these models require the initial
injection of cancer cells directly into the blood-
stream, hence the generation of these cells does
not truly reflect metastatic events that occur
from a primary tumor. Also, the MDA-MB-
231 cells are reported to be a “basal B” cell line
(Neve et al. 2006), or as more recently reported,
a claudin-low cell line (Prat et al., unpubl.);
therefore, the site-tropic signatures are superim-
posed on an already poor prognosis signature.
Using different approaches, other labora-
tories have also identified genes that are asso-
ciated with distant metastases. In 2006, Smid
et al. analyzed 107 microarrays of primary
breast tumors/patients that had all experienced
relapse (Smid et al. 2006). They found 69 genes
that were significantly different between pa-
tients that experienced relapse to bone as com-
pared to other distant sites, and the fibroblast
growth factor receptor signaling pathway was
identified as an important facilitator of bone
colonization. They ultimately developed a 31-
gene classifier that predicted bone relapse, and
which could possibly be used to recommend
bisphosphonate therapy to prevent osseous me-
tastasis. In 2008, Landemaine et al. identified
a six-gene signature that predicts lung metasta-
sis (Landemaine et al. 2008). This study took a
novel approach and compared the gene expres-
sion of five lung metastases against 18 metasta-
ses growing in other distant organs of patients.
In 2009, Hu et al. (2009) identified a vascular
endothelial growth factor (VEGF) signature that
was associated with distant metastases and
poor outcomes. This study compared gene ex-
pression profiles of 134 primary breast tumors,
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nine regional (lymph node) metastases, and 18
distant metastases in order to identify biological
features associated with the distant metastases.
Supervised analyses revealed very few differen-
ces between primary tumors and lymph node
metastases; however, distant metastases had
a distinct expression profile that was distin-
guished by the high expression of 13 genes,
including VEGF, most of which were HIF1-
alpha-regulated. The VEGF signature was able
to predict survival in patients with breast can-
cer, lung cancer, and glioblastomas, suggesting
that it may represent a widespread signature of
hypoxia that is applicable to multiple tumors
types.
Breast Cancer Stem Cells and Metastasis
Evidence for the existence of breast cancer stem
cells is growing (Al-Hajj et al. 2003; Ginestier
et al. 2007; Shipitsin et al. 2007; Wicha 2008),
and is covered in other articles on this topic;
however, mention of these unique cells is
required here, as it is likely that they may be
responsible for the formation of many meta-
stases. Recent studies have shown that normal
cells within the human and mouse mammary
tissues have various amounts of differentiation
and that certain rare cells, breast stem cells,
can give rise to fully functional epithelial ductal
structures (Raouf et al. 2008; Lim et al. 2009).
Our understanding of the molecular mecha-
nisms that give rise to breast tumors is incom-
plete, but it is likely that mutagenic agents
target specific breast cell subpopulations (i.e.,
the cell of origin for the tumor), which is likely
influenced by germline traits, to determine
whether or not aberrant cell proliferation
occurs. Thus, if highly differentiated cells
are transformed, then ERþ/luminal breast can-
cer may occur, while if more primitive stem, or
committed, progenitor cells are targeted, a more
stem-cell subtype (claudin-low) or luminal pro-
genitor (basal-like) tumor may arise (Lim et al.
2009; Prat and Perou 2009). Interestingly, em-
bryonic stem cell signatures have been identified
and are genomically more related to poorly dif-
ferentiated basal-like tumors than to luminal
tumors (Ben-Porath et al. 2008). Furthermore,
a recent study found that poorly differentiated
tumors contain a higher content of prospec-
tively isolated cancer stem cells compared to
well-differentiated tumors (Pece et al. 2010).
The incorporation of genome-wide expression
studies described above has further validated
the hypothesis that breast cancer cells within a
tumor differ in their metastatic potential. Since
breast cancer stem cells are relatively resistant
to both chemotherapy and radiation (Phillips
et al. 2006; Li et al. 2008), and because metas-
tases nearly always recur after treatment, it is
likely that stem cells are involved in metastatic
progression.
Summary
Without a doubt, the past decade of breast can-
cer research has produced more advances in
our understanding of the genetics of this disease
than ever before. This knowledge has been
significantly contributed to by the use of high-
throughput DNA microarray analyses of pri-
mary tumors and metastases. The future of
breast cancer genetic research looks encourag-
ing, as new technologies are emerging that
will couple DNA sequence and copy number
changes with gene and protein expression. All
of these advancements will further our under-
standing of this disease and will allow for im-
proved targeted therapeutics to inhibit tumor
growth and metastatic progression.
ACKNOWLEDGMENTS
We thank J. Chuck Harrell and Lisa Carey for
assistance in writing and editing this article.
REFERENCES
Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW,
Robertson JF, Nicholson RI, Ellis IO. 2004. Expression of
luminal and basal cytokeratins in human breast carci-
noma. J Pathol 203: 661–671.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ,
Clarke MF. 2003. Prospective identification of tumori-
genic breast cancer cells. Proc Natl Acad Sci U S A 100:
3983–3988.
Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM,
Mohsin SK, O’Connell P, Tsimelzon A, Medina D.
2008. Ductal carcinoma in situ and the emergence of
System Biology and Genomics of Breast Cancer
Cite this article as Cold Spring Harb Perspect Biol 2011;3:a003293 13
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
diversity during breast cancer evolution. Clin Cancer Res
14: 370–378.
Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C,
Richon C, Yan K, Wang B, Vassal G, et al. 2009. Molecular
characterization of breast cancer with high-resolution
oligonucleotide comparative genomic hybridization ar-
ray. Clin Cancer Res 15: 441–451.
Asselin-Labat ML, Sutherland KD, Barker H, Thomas R,
Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld
FG, van der Wees J, et al. 2006. Gata-3 is an essential reg-
ulator of mammary-gland morphogenesis and luminal-
cell differentiation. Nat Cell Biol 9: 201–209.
Baudis M. 2007. Genomic imbalances in 5918 malignant
epithelial tumors: An explorative meta-analysis of chro-
mosomal CGH data. BMC Cancer 7: 226.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. 2007.
Descriptive analysis of estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, and HER2-negative
invasive breast cancer, the so-called triple-negative phe-
notype: A population-based study from the California
Cancer Registry. Cancer 109: 1721–1728.
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev
A, Weinberg RA. 2008. An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive
human tumors. Nat Genet 40: 499–507.
Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, Marron
JS. 2004. Adjustment of systematic microarray data
biases. Bioinformatics 20: 105–114.
Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-
Boussard T, Lonning PE, Tibshirani R, Børresen-Dale
AL, Pollack JR. 2006. Distinct patterns of DNA copy
number alteration are associated with different clinicopa-
thological features and gene-expression subtypes of
breast cancer. Genes Chromosom Cancer 45: 1033–1040.
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen
DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens
JA, et al. 2009. Genes that mediate breast cancer metasta-
sis to the brain. Nature 459: 1005–1009.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D,
Conway K, Karaca G, Troester MA, Tse CK, Edmiston
S, et al. 2006. Race, breast cancer subtypes, and survival
in the Carolina Breast Cancer Study. JAMA 295: 2492–
2502.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F,
Ollila DW, Sartor CI, Graham ML, Perou CM. 2007.
The triple negative paradox: Primary tumor chemosensi-
tivity of breast cancer subtypes. Clin Cancer Res 13:
2329–2334.
Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ,
Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR,
et al. 2005. Chromosome-wide mapping of estrogen
receptor binding reveals long-range regulation requiring
the forkhead protein FoxA1. Cell 122: 33–43.
Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB,
Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown
PO. 2004. Gene expression signature of fibroblast serum
response predicts human cancer progression: Similarities
between tumors and wounds. PLoS Biol 2: E7.
Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta
R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al.
2006. Genomic and transcriptional aberrations linked
to breast cancer pathophysiologies. Cancer Cell 10:
529–541.
Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-
Morais NL, Thorne NP, Costa JL, Pinder SE, van de
Wiel MA, Green AR, et al. 2007. High-resolution
aCGH and expression profiling identifies a novel
genomic subtype of ER negative breast cancer. Genome
Biol 8: R215.
Chung CH, Bernard PS, Perou CM. 2002. Molecular por-
traits and the family tree of cancer. Nat Genet 32:
533–540.
Climent J, Garcia JL, Mao JH, Arsuaga J, Perez-Losada J.
2007. Characterization of breast cancer by array compa-
rative genomic hybridization. Biochem Cell Biol 85:
497–508.
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM,
Sjolund A, Rimm DL, Wong H, Rodriguez A, Her-
schkowitz JI, et al. 2009. Residual breast cancers after
conventional therapy display mesenchymal as well as
tumor-initiating features. Proc Natl Acad Sci U S A 106:
13820–13825.
DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D,
Kolhatkar N, Coussens LM. 2009. CD4(þ) T cells regu-
late pulmonary metastasis of mammary carcinomas by
enhancing protumor properties of macrophages. Cancer
Cell 16: 91–102.
Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS,
Brown M. 2007. Positive cross-regulatory loop ties
GATA-3 to estrogen receptor alpha expression in breast
cancer. Cancer Res 67: 6477–6483.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB,
van’t Veer LJ, Perou CM. 2006. Concordance among
gene-expression-based predictors for breast cancer.
N Engl J Med 355: 560–569.
Fidler IJ, Kripke ML. 1977. Metastasis results from preexist-
ing variant cells within a malignant tumor. Science 197:
893–895.
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M,
Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu
A, et al. 2008. Stromal gene expression predicts clinical
outcome in breast cancer. Nat Med 14: 518–527.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink
M, Mortimer P, Swaisland H, Lau A, O’Connor MJ,
et al. 2009. Inhibition of poly(ADP-ribose) polymerase
in tumors from BRCA mutation carriers. N Engl J Med
361: 123–134.
Foulkes WD. 2004. BRCA1 functions as a breast stem cell
regulator. J Med Genet 41: 1–5.
Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin
JR, Wong N, Trudel M, Akslen LA. 2003. Germline
BRCA1 mutations and a basal epithelial phenotype in
breast cancer. J Natl Cancer Inst 95: 1482–1485.
Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves
R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, et al. 2006.
Breast tumor copy number aberration phenotypes and
genomic instability. BMC Cancer 6: 96.
Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew
K, Moore D, Rabban J, Chen YY, Kerlikowske K, Tlsty
TD. 2007. Abrogated response to cellular stress identi-
fies DCIS associated with subsequent tumor events
and defines basal-like breast tumors. Cancer Cell 12:
479–491.
C.M. Perou and A.-L. Børresen-Dale
14 Cite this article as Cold Spring Harb Perspect Biol 2011;3:a003293
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F,
Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al. 2007. ALDH1 is a marker of normal and
malignant human mammary stem cells and a predictor
of poor clinical outcome. Cell Stem Cell 1: 555–567.
Git A, Spiteri I, Blenkiron C, Dunning MJ, Pole JC, Chin SF,
Wang Y, Smith J, Livesey FJ, Caldas C. 2008. PMC42, a
breast progenitor cancer cell line, has normal-like
mRNA and microRNA transcriptomes. Breast Cancer
Res 10: R54.
Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye
DK, Buzdar AU. 1996. Long-term follow-up of patients
with complete remission following combination chemo-
therapy for metastatic breast cancer. J Clin Oncol 14:
2197–2205.
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gil-
crease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin
A, Agarwal R, Joy C, et al. 2009. Characterization of a nat-
urally occurring breast cancer subset enriched in
epithelial-to-mesenchymal transition and stem cell char-
acteristics. Cancer Res 69: 4116–4124.
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J,
Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrase-
kharan S, et al. 2007. Identification of conserved gene
expression features between murine mammary carci-
noma models and human breast tumors. Genome Biol
8: R76.
Herschkowitz JI, He X, Fan C, Perou CM. 2008. The func-
tional loss of the retinoblastoma tumor suppressor is a
common event in basal-like and luminal B breast carci-
nomas. Breast Cancer Res 10: R75.
Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E,
Esposito D, Alexander J, Troge J, Grubor V, et al. 2006.
Novel patterns of genome rearrangement and their asso-
ciation with survival in breast cancer. Genome Res 16:
1465–1479.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C,
Carey LA, Reynolds E, Dressler L, et al. 2006. The molec-
ular portraits of breast tumors are conserved across
microarray platforms. BMC Genomics 7: 96.
Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA,
Subramanian S, West R, Ikpatt F, et al. 2009. A compact
VEGF signature associated with distant metastases and
poor outcomes. BMC Med 7: 9.
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R,
Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O,
et al. 2009. Population differences in breast cancer: Survey
in indigenous African women reveals over-representation
of triple-negative breast cancer. J Clin Oncol 27: 4515–
4521.
Joyce JA, Pollard JW. 2009. Microenvironmental regulation
of metastasis. Nat Rev Cancer 9: 239–252.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM,
Cordon-Cardo C, Guise TA, Massague J. 2003. A multi-
genic program mediating breast cancer metastasis to
bone. Cancer Cell 3: 537–549.
Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin
DP. 2004. The role of BRCA1 in the cellular response to
chemotherapy. J Natl Cancer Inst 96: 1659–1668.
Korsching E, Packeisen J, Helms MW, Kersting C, Voss R,
van Diest PJ, Brandt B, van der Wall E, Boecker W, Burger
H. 2004. Deciphering a subgroup of breast carcinomas
with putative progression of grade during carcinogenesis
revealed by comparative genomic hybridisation (CGH)
and immunohistochemistry. Br J Cancer 90: 1422–1428.
Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. 2006.
GATA-3 maintains the differentiation of the luminal cell
fate in the mammary gland. Cell 127: 1041–1055.
Landemaine T, Jackson A, Bellahcene A, Rucci N, Sin S,
Abad BM, Sierra A, Boudinet A, Guinebretiere JM, Rice-
vuto E, et al. 2008. A six-gene signature predicting breast
cancer lung metastasis. Cancer Res 68: 6092–6099.
Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR,
Ikdahl T, Karesen R, Børresen-Dale AL, Jeffrey SS. 2007.
TP53 mutation status and gene expression profiles are
powerful prognostic markers of breast cancer. Breast
Cancer Res 9: R30.
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF,
Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al.
2008. Intrinsic resistance of tumorigenic breast cancer
cells to chemotherapy. J Natl Cancer Inst 100: 672–679.
Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-
Labat ML, Gyorki DE, Ward T, Partanen A, et al. 2009.
Aberrant luminal progenitors as the candidate target
population for basal tumor development in BRCA1
mutation carriers. Nat Med 15: 907–913.
Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jack-
son S, Tse CK, Nyante S, Millikan RC. 2007. Identifica-
tion of a basal-like subtype of breast ductal carcinoma
in situ. Hum Pathol 38: 197–204.
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B,
Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley
JW. 2008. Race and triple negative threats to breast cancer
survival: A population-based study in Atlanta, GA. Breast
Cancer Res Treat 113: 357–370.
Mass RD. 2004. The HER receptor family: A rich target for
therapeutic development. Int J Radiat Oncol Biol Phys 58:
932–940.
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K,
Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S,
et al. 2007. Epidemiology of basal-like breast cancer.
Breast Cancer Res Treat 109: 123–139.
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD,
Viale A, Olshen AB, Gerald WL, Massague J. 2005. Genes
that mediate breast cancer metastasis to lung. Nature 436:
518–524.
Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P,
Schwartz GF, Park PK, Rosenberg AL, Brill K, et al.
2007. Differences in breast carcinoma characteristics
in newly diagnosed African-American and Caucasian
patients: A single-institution compilation compared with
the National Cancer Institute’s Surveillance, Epidemiol-
ogy, and End Results database. Cancer 110: 876–884.
Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG,
Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim
G, Karesen R, et al. 2007. Presence of bone marrow
micrometastasis is associated with different recurrence
risk within molecular subtypes of breast cancer. Mol
Oncol 1: 160–171.
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T,
Clark L, Bayani N, Coppe JP, Tong F, et al. 2006. A collec-
tion of breast cancer cell lines for the study of functionally
distinct cancer subtypes. Cancer Cell 10: 515–527.
System Biology and Genomics of Breast Cancer
Cite this article as Cold Spring Harb Perspect Biol 2011;3:a003293 15
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
Nordgard SH, Johansen FE, Alnaes GI, Bucher E, Syvanen
AC, Naume B, Børresen-Dale AL, Kristensen VN. 2008.
Genome-wide analysis identifies 16q deletion associated
with survival, molecular subtypes, mRNA expression,
and germline haplotypes in breast cancer patients. Genes
Chromosom Cancer 47: 680–696.
Nowell PC, Hungerford DA. 1960. Chromosome studies on
normal and leukemic human leukocytes. J Natl Cancer
Inst 25: 85–109.
O’Shaughnessy J, Osborne C, Pippen J, Patt D, Rocha C,
Ossovshaya V, Sherman BM, Bradley CR. 2009. Updated
results of a randomized phase II study demonstrating
efficacy and safety of BSI-201, a PARP inhibitor, in com-
bination with gemcitabine/carboplatin in metastatic
triple-negative breast cancer. San Antonio Breast Cancer
Symposium, San Antonio, Texas.
Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J,
Carey LA, Perou CM. 2006. Estrogen-regulated genes pre-
dict survival in hormone receptor-positive breast can-
cers. J Clin Oncol 24: 1656–1664.
Olopade OI, Grushko T. 2001. Gene-expression profiles in
hereditary breast cancer. N Engl J Med 344: 2028–2029.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner
FL, Walker MG, Watson D, Park T, et al. 2004. A multi-
gene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med 351: 2817–
2826.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M,
Baehner FL, Watson D, Bryant J, et al. 2006. Gene expres-
sion and benefit of chemotherapy in women with node-
negative, estrogen receptor-positive breast cancer. J Clin
Oncol 24: 3726–3734.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vick-
ery T, Davies S, Fauron C, He X, Hu Z, et al. 2009. Super-
vised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol 27: 1160–1167.
Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M,
Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP.
2010. Biological and molecular heterogeneity of breast
cancers correlates with their cancer stem cell content.
Cell 140: 62–73.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees
CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al.
2000. Molecular portraits of human breast tumours.
Nature 406: 747–752.
Phillips TM, McBride WH, Pajonk F. 2006. The response of
CD24(-/low)/CD44þ breast cancer-initiating cells to
radiation. J Natl Cancer Inst 98: 1777–1785.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Gold-
hirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R,
Jackisch C, et al. 2005. Trastuzumab after adjuvant che-
motherapy in HER2-positive breast cancer. N Engl J
Med 353: 1659–1672.
Prat A, Perou CM. 2009. Mammary development meets can-
cer genomics. Nat Med 15: 842–844.
Prat A, Parker JS, Fan C, Karginova O, Livasy C, Herschko-
witz J, He X, Perou CM. Submitted. Phenotypic and
molecular characterization of the claudin-low intrinsic
subtype of breast cancer.
Ramaswamy S, Ross KN, Lander ES, Golub TR. 2003. A
molecular signature of metastasis in primary solid
tumors. Nat Genet 33: 49–54.
Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, Iscove
N, Jones S, McKinney S, Emerman J, et al. 2008. Tran-
scriptome analysis of the normal human mammary cell
commitment and differentiation process. Cell Stem Cell
3: 109–118.
Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO,
Borg A, Karhu R, Tanner M, Tirkkonen M, Isola J.
2003. Patterns of chromosomal imbalances defines sub-
groups of breast cancer with distinct clinical features
and prognosis. A study of 305 tumors by comparative
genomic hybridization. Cancer Res 63: 8861–8868.
Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M,
Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan
S. 2006. X chromosomal abnormalities in basal-like
human breast cancer. Cancer Cell 9: 121–132.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofa-
nilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner
P, et al. 2005. Breast cancer molecular subtypes respond
differently to preoperative chemotherapy. Clin Cancer
Res 11: 5678–5685.
Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin
P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin
SF, et al. 2010. Genomic architecture characterizes tumor
progression paths and fate in breast cancer patients. Sci
Transl Med 2: 38ra47.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM,
Richardson A, Sledge GW, Carey LA. 2008. Triple-
negative breast cancer: Risk factors to potential targets.
Clin Cancer Res 14: 8010–8018.
Shipitsin M, Campbell LL, Argani P, Weremowicz S,
Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya
T, Beroukhim R, Hu M, et al. 2007. Molecular definition
of breast tumor heterogeneity. Cancer Cell 11: 259–273.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A,
McGuire WL. 1987. Human breast cancer: Correlation
of relapse and survival with amplification of the
HER-2/neu oncogene. Science 235: 177–182.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG,
Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A.
1989. Studies of the HER-2/neu proto-oncogene in
human breast and ovarian cancer. Science 244: 707–712.
Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D,
Martens JW, Foekens JA. 2006. Genes associated with
breast cancer metastatic to bone. J Clin Oncol 24: 2261–
2267.
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG,
Foekens JA, Martens JW. 2008. Subtypes of breast cancer
show preferential site of relapse. Cancer Res 68: 3108–
3114.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen
H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al.
2001. Gene expression patterns of breast carcinomas dis-
tinguish tumor subclasses with clinical implications. Proc
Natl Acad Sci U S A 98: 10869–10874.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A,
Deng S, Johnsen H, Pesich R, Geisler S, et al. 2003.
Repeated observation of breast tumor subtypes in inde-
pendent gene expression data sets. Proc Natl Acad Sci U
S A 100: 8418–8423.
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM,
Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. 2003.
Breast cancer classification and prognosis based on
C.M. Perou and A.-L. Børresen-Dale
16 Cite this article as Cold Spring Harb Perspect Biol 2011;3:a003293
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
gene expression profiles from a population-based study.
Proc Natl Acad Sci U S A 100: 10393–10398.
Teixeira MR, Pandis N, Heim S. 2002. Cytogenetic clues
to breast carcinogenesis. Genes Chromosom Cancer 33:
1–16.
Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC,
Perou CM. 2009. In vitro and in vivo analysis of B-Myb in
basal-like breast cancer. Oncogene 28: 742–751.
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J,
Kallioniemi OP. 1998. Molecular cytogenetics of primary
breast cancer by CGH. Genes Chromosom Cancer 21:
177–184.
Tsarouha H, Pandis N, Bardi G, Teixeira MR, Andersen JA,
Heim S. 1999. Karyotypic evolution in breast carcinomas
with i(1)(q10) and der(1;16)(q10;p10) as the primary
chromosome abnormality. Cancer Genet Cytogenet 113:
156–161.
Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Lan-
gerod A, Karesen R, Oh DS, Dressler LG, et al. 2004.
Mutation of GATA3 in human breast tumors. Oncogene
23: 7669–7678.
van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA,
Mao M Peterse HL, van der Kooy K, Marton MJ, Wit-
teveen AT, et al. 2002. Gene expression profiling predicts
clinical outcome of breast cancer. Nature 415: 530–536.
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Vos-
kuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ,
et al. 2002. A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med 347: 1999–2009.
Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar
NT, van Roy F, Cornelisse CJ, Peterse JL, van de Vijver MJ.
1997. E-cadherin inactivation in lobular carcinoma in
situ of the breast: An early event in tumorigenesis. Br J
Cancer 76: 1131–1133.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F,
Talantov D, Timmermans M, Meijer-van Gelder ME, Yu
J, et al. 2005. Gene-expression profiles to predict distant
metastasis of lymph-node-negative primary breast can-
cer. Lancet 365: 671–679.
Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL,
van’t Veer LJ. 2003. Gene expression profiles of primary
breast tumors maintained in distant metastases. Proc
Natl Acad Sci U S A 100: 15901–15905.
Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas
AM, Perou CM, Van’t Veer LJ. 2005. Molecular portraits
and 70-gene prognosis signature are preserved through-
out the metastatic process of breast cancer. Cancer Res
65: 9155–9158.
West M, Blanchette C, Dressman H, Huang E, Ishida S,
Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR.
2001. Predicting the clinical status of human breast can-
cer by using gene expression profiles. Proc Natl Acad Sci U
S A 98: 11462–11467.
Whitfield ML, George LK, Grant GD, Perou CM. 2006.
Common markers of proliferation. Nat Rev Cancer 6:
99–106.
Wicha MS. 2008. Cancer stem cell heterogeneity in heredi-
tary breast cancer. Breast Cancer Res 10: 105.
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA,
Peplonska B, Hewitt SM, Anderson WF, Szeszenia-
Dabrowska N, Bardin-Mikolajczak A, et al. 2007. Differ-
ences in risk factors for breast cancer molecular subtypes
in a population-based study. Cancer Epidemiol Bio-
markers Prev 16: 439–443.
Yu K, Lee CH, Tan PH, Tan P. 2004. Conservation of breast
cancer molecular subtypes and transcriptional patterns
of tumor progression across distinct ethnic populations.
Clin Cancer Res 10: 5508–5517.
System Biology and Genomics of Breast Cancer
Cite this article as Cold Spring Harb Perspect Biol 2011;3:a003293 17
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
November 3, 2010
2011; doi: 10.1101/cshperspect.a003293 originally published onlineCold Spring Harb Perspect Biol 
 
Charles M. Perou and Anne-Lise Børresen-Dale
 
Systems Biology and Genomics of Breast Cancer
Subject Collection  The Mammary Gland as an Experimental Model
Gland Development and Cancer
On the Role of the Microenvironment in Mammary
Derek Radisky
Metalloproteinases Couple Form with Function
On How Mammary Gland Reprogramming
Bonnie F. Sloane
Breast Cancer Biology
On Using Functional Genetics to Understand
Kornelia Polyak
Mammary Gland Development
On Molecular Mechanisms Guiding Embryonic
Gertraud W. Robinson
the Mammary Gland
On Oncogenes and Tumor Suppressor Genes in
Rushika M. Perera and Nabeel Bardeesy
On Stem Cells in the Human Breast
Mark A. LaBarge
Cancer
On Leukocytes in Mammary Development and
Cyrus M. Ghajar
Discovery, Function, and Current Status
On Murine Mammary Epithelial Stem Cells:
Jeffrey M. Rosen
Differentiation and Breast Tumorigenesis
On Chromatin Remodeling in Mammary Gland
Kornelia Polyak
On In Vivo Imaging in Cancer
David Piwnica-Worms
On Hormone Action in the Mammary Gland
J.M. Rosen
Models of Breast Cancer
The Utility and Limitations of Mouse−−in Context
 Choosing a Mouse Model: Experimental Biology
Alexander D. Borowsky
Breast Cancer
 Biology in Mammary Development andβTGF-
Harold Moses and Mary Helen Barcellos-Hoff Tumor Progression
Mechanosignaling in Normal Development and 
Mammary Gland ECM Remodeling, Stiffness, and
Pepper Schedin and Patricia J. Keely
Engineered Mice
House Mouse to the Development of Genetically
Biologist: From the Initial Observations in the 
A Compendium of the Mouse Mammary Tumor
Robert D. Cardiff and Nicholas Kenney
Mammary Gland Development
Molecular Mechanisms Guiding Embryonic
Pamela Cowin and John Wysolmerski
http://cshperspectives.cshlp.org/cgi/collection/ For additional articles in this collection, see 
Copyright © 2011 Cold Spring Harbor Laboratory Press; all rights reserved
 on July 15, 2020 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
